ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,721 to 3,740 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection689 of 947

547 of 945

14.9 points

10.6 to 19.1

1,892NCT06060457

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Required Additional Childcare390 of 1,190

220 of 701

1.4 points

-3.0 to 5.7

1,891NCT02297815

Comparative Effectiveness of Antibiotics for Respiratory Infections

Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Completion of TB Evaluation266 of 560

1,144 of 1,329

-38.6 points

-43.0 to -34.0

1,889NCT05640648

Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda

Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events568 of 945

594 of 943

-2.9 points

-7.3 to 1.5

1,888NCT00321620

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Dalteparin vs Placebo: serious adverse events133 of 934

66 of 950

7.3 points

4.5 to 10.1

1,884NCT00786474

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)3 of 942

12 of 940

-1.0 points

-1.9 to -0.1

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion1 of 942

11 of 940

-1.1 points

-2.0 to -0.4

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)3 of 942

12 of 940

-1.0 points

-1.9 to -0.1

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)4 of 942

12 of 940

-0.9 points

-1.8 to 0.0

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke40 of 942

77 of 940

-3.9 points

-6.2 to -1.8

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Graft Stenosis or Occlusion0 of 942

11 of 940

-1.2 points

-2.1 to -0.5

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)4 of 942

13 of 940

-1.0 points

-2.0 to -0.1

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia40 of 942

82 of 940

-4.5 points

-6.7 to -2.3

1,882NCT01205776

EXCEL Clinical Trial

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Protocol Defined MI34 of 942

58 of 940

-2.6 points

-4.6 to -0.6

1,882NCT01205776

EXCEL Clinical Trial

Amulet vs WATCHMAN (Control): deaths from any cause251 of 934

263 of 944

-1.0 points

-5.0 to 3.0

1,878NCT02879448

AMPLATZER™ Amulet™ LAA Occluder Trial

Amulet vs WATCHMAN (Control): serious adverse events542 of 934

535 of 944

1.4 points

-3.1 to 5.8

1,878NCT02879448

AMPLATZER™ Amulet™ LAA Occluder Trial

Immediate Return of Results vs Delayed Return of Results: deaths from any cause3 of 953

4 of 921

-0.1 points

-0.8 to 0.5

1,874NCT06748040

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy

EZ/Simva 10/40 mg vs Placebo: Hospitalization for Unstable Angina5 of 944

8 of 929

-0.3 points

-1.2 to 0.5

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)333 of 944

355 of 929

-2.9 points

-7.3 to 1.4

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Death (Any Cause)105 of 944

100 of 929

0.4 points

-2.5 to 3.2

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=187"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=187

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT06060457-0dcbee98",
        "title": "Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection",
        "summary": "689 of 947 against 547 of 945; risk difference 14.9 points, 95% interval 10.6 to 19.1; NCT06060457, A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age",
        "record": "/library/comparisons/NCT06060457-0dcbee98",
        "nct_id": "NCT06060457",
        "kind": "outcome",
        "participants": 1892,
        "risk_difference": {
          "value": 0.14872473922104334,
          "lower": 0.10604351635836287,
          "upper": 0.1906493969788044
        },
        "group_1": "689 of 947",
        "group_2": "547 of 945",
        "difference": "14.9 points",
        "interval": "10.6 to 19.1",
        "trial_title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age"
      },
      {
        "id": "NCT02297815-eb9a7ec7",
        "title": "Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Required Additional Childcare",
        "summary": "390 of 1190 against 220 of 701; risk difference 1.4 points, 95% interval -3.0 to 5.7; NCT02297815, Comparative Effectiveness of Antibiotics for Respiratory Infections",
        "record": "/library/comparisons/NCT02297815-eb9a7ec7",
        "nct_id": "NCT02297815",
        "kind": "outcome",
        "participants": 1891,
        "risk_difference": {
          "value": 0.013893717258658123,
          "lower": -0.029984321026532465,
          "upper": 0.05684991910481427
        },
        "group_1": "390 of 1,190",
        "group_2": "220 of 701",
        "difference": "1.4 points",
        "interval": "-3.0 to 5.7",
        "trial_title": "Comparative Effectiveness of Antibiotics for Respiratory Infections"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=188",
  "request_id": "f0_ZoM5xQajp2GCb"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?